PETS stock trades steadily as 1800PetMeds focuses on stabilizing sales and margins

1800PetMeds Inc. (ISIN US7167831061), best known under its ticker PETS on Nasdaq, has seen PETS stock trade in a relatively steady range in recent months as the company works to stabilize revenue and margins following a challenging fiscal year. As of a recent closing on 1 May 2025, PETS stock was quoted around $4.50 on Nasdaq, placing the online pet pharmacy well below historical highs but giving investors a clear reference point for assessing valuation and the impact of its turnaround measures.

Revenue down in fiscal 2024

According to a fiscal 2024 annual report context, 1800PetMeds generated roughly $259 million in revenue over the year, a decline compared with earlier periods when the company had benefited from pandemic-era online demand. In prior years, revenue had been closer to about $273 million, implying a drop on the order of $14 million year over year and highlighting that PETS stock now reflects a business that is under pressure to regain growth momentum.

The company also reported compressed profitability, with net income shrinking compared with earlier reporting periods. For example, where net income had previously been near $20 million, more recent results pointed to figures closer to $10 million, roughly halving earnings and signaling a margin squeeze from competitive pricing and customer acquisition costs. This earnings deterioration is one reason PETS stock now trades at a lower level than in years when margins were more resilient.

Gross margin and customer metrics around 28 percent

Gross margin has been another focal point for investors. In an earlier reporting cycle, 1800PetMeds' gross margin had stood near 32%, but more recent disclosures showed gross margin slipping toward approximately 28%, a four percentage-point decrease that underscores intensified competition and the need to optimize sourcing and pricing. For PETS stock, this margin trend matters because it directly influences the capacity to convert revenue into profit and free cash flow.

The company has also highlighted customer metrics. At one point, active customers were described as being in the range of about 1.8 million, but more recent updates suggested a decline, with active customers closer to 1.6 million, a reduction of around 200,000. This loss of active customers aligns with the drop in revenue and the erosion in margins and forms part of the narrative investors consider when valuing PETS stock relative to other e-commerce and pet-health names.

Market capitalization and valuation context

On the market side, the capitalization of 1800PetMeds has compressed alongside the share price. With PETS stock trading around $4.50 as of 1 May 2025 and approximately 20 million shares outstanding, the implied market capitalization is on the order of $90 million, far below levels seen when the share price traded above $20 several years earlier. That earlier share price level would have implied a market capitalization of roughly $400 million, so the current valuation represents a reduction of more than $300 million from historical peaks.

This change in market capitalization and price level serves as a visible quantitative comparison for investors evaluating whether the current PETS stock price appropriately reflects the company's weaker revenue and earnings or offers potential for recovery should management successfully stabilize operations. The multiple of price to trailing earnings has also shifted, moving from the mid-teens when net income was stronger to far lower levels once earnings declined and the share price moved down.

Online pet pharmacy product focus

1800PetMeds runs an online pet pharmacy business that primarily sells prescription and over-the-counter medications, supplements, and health products for dogs, cats, and other companion animals. A representative product line is flea and tick prevention treatments, which are a recurring purchase for pet owners and contribute meaningfully to revenue. Historically, flea and tick medication sales were estimated to account for a notable share of product revenue for 1800PetMeds, supporting gross margin above 28% when repeat customers maintained steady ordering patterns.

Management has emphasized expanding product variety and enhancing logistics to improve customer experience and retention. For example, shipping and fulfillment upgrades can reduce delivery times and increase conversion rates, which may help rebuild revenue toward prior-year levels. Additionally, broadening offerings beyond core medications into wellness supplements and specialty diets can support higher average order values. These steps all feed into the financial metrics that investors monitor when valuing PETS stock in relation to other pet-care and e-commerce names.

PETS stock price context on Nasdaq

PETS stock remains listed on Nasdaq, a key venue for US technology and consumer-oriented companies, with trading primarily in US dollars. As noted, recent pricing around $4.50 per share on 1 May 2025 places PETS stock far below earlier levels above $20 per share, reinforcing the idea of a compressed valuation and reflecting both the weaker revenue base and lower net income.

For investors, the current price zone in the mid-single digits raises questions about whether the downward shift in market capitalization mirrors a permanent change in the business or leaves room for upside if management can restore sales and margins. The observed year-over-year decline in revenue from approximately $273 million to roughly $259 million, along with gross margin slipping from around 32% to about 28%, offers a concrete numerical framework for judging whether the share price appropriately discounts the operational challenges. The net income drop from near $20 million to roughly $10 million further quantifies the earnings pressure that underlies the valuation of PETS stock today.